Skip to content
DataLookout
Menu

NCT07722312

S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation

StatusNot Yet Recruiting
PhasePhase 1/2
SponsorServier
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date pushed from Oct 20, 2026 to Feb 1, 2027
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 37 words
    • Secondary endpoints: details revised at 3 of 21 entries
  2. Notable Start date: Sep 20, 2026 to Oct 20, 2026v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of Adverse Events (AEs)
Timeframe: Through Safety Follow-up (Approximately 3 years)
Severity of AEs
Timeframe: Through Safety Follow-up (Approximately 3 years)
Number of Serious Adverse Events (SAEs)
Timeframe: Through Safety Follow-up (Approximately 3 years)
Number of changes in laboratory values
Timeframe: Through Safety Follow-up (Approximately 3 years)
Number of changes in electrocardiogram (ECG)
Timeframe: Through Safety Follow-up (Approximately 3 years)
Number of changes in vital signs
Timeframe: Through Safety Follow-up (Approximately 3 years)
Number of AEs leading to dose interruption
Timeframe: Through Safety Follow-up (Approximately 3 years)
Number of AEs leading to dose modification
Timeframe: Through Safety Follow-up (Approximately 3 years)
Number of AEs leading to dose delays
Timeframe: Through Safety Follow-up (Approximately 3 years)
Number of AEs leading to permanent treatment discontinuation
Timeframe: Through Safety Follow-up (Approximately 3 years)
Complete remission (CR) + Complete remission with partial recovery of hematology (CRh) rate
Timeframe: Through Long-term Follow-up (Approximately 5 years)

Secondary (21)

Overall response rate (ORR)
Composite complete remission (CRc) rate
CR rate
Rate of CR/CRh Minimal residual disease (MRD) negativity
Duration of response (DOR)
Show 16 moreShow less
Time to response (TTR)
Transfusion independence 56 days (TI-56)
Transfusion independence 112 days (TI-112)
Event free survival (EFS)
Cumulative relapse rate (CIR)
Cumulative mortality (CID)
Overall survival (OS)
Quality of Life (QoL) measured via EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L)
QoL measured via Hematological malignancy specific patient-reported outcome (HM-PRO)
Health economic outcomes measured via EQ-5D-5L
Health economic outcomes measured via HM-PRO
Ability to proceed to hematopoietic stem cell transplantation (HSCT) as assessed by the investigator
Plasma concentration of S243249 and relevant metabolites
Tmax
Cmax
AUC0-t

Arms and interventions

Phase 1 Dose Optimization: Cohort 1Experimental

For participants without strong CYP3A4 inhibitors

Phase 1 Dose Optimization: Cohort 2Experimental

For participants without strong CYP3A4 inhibitors

Phase 1 Dose Optimization: Cohort 3Experimental

For participants with strong CYP3A4 inhibitors

Phase 1 Dose Optimization: Cohort 4Experimental

For participants with strong CYP3A4 inhibitors

Drugs: S243249 600mg, S243249 400mg, S243249 450mg, S243249 300mg